Navigation Links
Occlutech Obtains CE Mark for the new Generation PFO & ASD Occluders
Date:5/12/2009

JENA, Germany, May 12 /PRNewswire/ -- Occlutech, the leading European developer of septum occluders, today announced that it has obtained CE mark approval for its new generation ASD and PFO occluders, the Figulla Flex.

The Figulla Flex ASD and PFO occluders encompass a new innovative delivery system, making the use of a threaded hub unnecessary. The implantation of the occluder is facilitated by the ability of the delivery system to allow a 45 degree angle before release.

The Occlutech Figulla Flex will be exhibited and demonstrated at the PCR vascular intervention meeting in Barcelona from May 19th to May 22nd.

Occlusion devices are used to treat structural heart disease, including structural heart defects and abnormalities such as Atrial Septal Defects, (ASD), and Patent Foramen Ovale (PFO, an undesired channel between the heart's two atria, present in up to 25% of the population), in minimally invasive, non-surgical procedures. The market for PFO occluders is expected to expand significantly as the link between PFO and stroke, that is the third most common cause of death, as well as severe migraine becomes increasingly well documented.

    Contact:

    Tor Peters
    info@occlutech.de
    Tel: +49-3641-67-51-29

    Katrin Biedermann
    katrin.biedermann@occlutech.de
    Tel.: +49-3641-67-51-20


'/>"/>
SOURCE Occlutech GmbH
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. AGA Medical Corporation Begins Proceedings Against Occlutech to Recover Damages
2. AGA Medical to Appeal Ruling by Dutch Court in Lawsuit With Occlutech GmbH
3. Occlutech Wins Confirmation of its Intellectual Property Position Versus AGA Medical Patent by AIPPI
4. Hard To Treat Diseases (HTDS) Obtains HAS Certificate
5. American Biotech Labs(R) Obtains FDA Approval for New Wound Care Gel Product
6. High dosage brachytherapy obtains excellent results in head and neck tumors
7. China Sky One Medical, Inc. Obtains SFDA Approval for Policresulen Vaginal Suppositories
8. Cynosure Obtains Favorable Markman Rulings in Patent Infringement Case Against CoolTouch
9. Nostrum Pharmaceuticals Obtains Worldwide Licensing Rights From IMTECH for Clinical Development of the Small Molecule Caerulomycin and Its Proprietary Derivatives for Their Novel Indication of Immunosuppression
10. Steve Teal, Santa Rosa Attorney, Obtains $850,000 for Client in Highest Hospital Negligence Verdict in Mendocino County
11. New York Attorney Obtains $2.25 Million Verdict for Client Injured on Grounds of Bronx Eye Surgery Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... Vighter ... the same time by providing Prehospital Trauma Life Support (PHTLS) course scholarships to ... premier prehospital trauma education developed in cooperation with the American College of Surgeons ...
(Date:3/24/2017)... ... March 24, 2017 , ... Digital Scientists, a software innovation ... the opening of a Greenville, South Carolina location. The lab has set ... Greenville. , “We’ve been working with South Carolina clients for years from our office ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... Texas ... which can be found at 9618 Huebner Road. The clinic is the group’s 7th ... Clinic Director, and Dr. Ali Higgins, PT, will provide care from the clinic, which ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... Center, Sedona, Arizona’s Premier Center for Shamanic Healing and Spiritual Awakening, proudly ... Delgado, June 9--24, 2017. This sacred and spiritual journey during the Summer ...
(Date:3/24/2017)... ... 24, 2017 , ... Northridge dentists, Dr. Michel ... sleep apnea and TMJ at their office. TMJ, or temporomandibular joint disorder, has ... type, is increasingly being treated at dental offices with newly developed procedures and ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... -- Eli Lilly and Company (NYSE: LLY ... in its U.S. operations in 2017. The company,s ... research laboratories, manufacturing sites, and general and administrative ... for Lilly products, as well as its robust ... pain, diabetes and other unmet medical needs.  ...
(Date:3/24/2017)... Tenn. , March 23, 2017  Provectus ... or the "Company"), a clinical-stage oncology and dermatology ... announced Definitive Financing Commitment Term Sheet (the "Definitive ... a group of the Company,s stockholders, who are ... Group" in a Form 8-K filed with the ...
(Date:3/23/2017)... , Mar 23, 2017 Research and ... Analysis & Trends - Industry Forecast to 2025" report to ... ... of around 6.9% over the next decade to reach approximately $3.5 ... estimates and forecasts for all the given segments on global as ...
Breaking Medicine Technology: